Kotaro Hayashi

Itabashi, 1738605, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Early Temporal Dissociation Between C-Reactive Protein and Neutrophil Counts After Spesolimab Treatment in Generalized Pustular Psoriasis.

Early Temporal Dissociation Between C-Reactive Protein and Neutrophil Counts After Spesolimab Treatment in Generalized Pustular Psoriasis.

Journal: Acta dermato-venereologica

Published: June 19, 2026

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis.

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis.

Journal: JAAD international

Published: January 21, 2026

A 308-nm Excimer Lamp Ameliorates MC903-Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin.

A 308-nm Excimer Lamp Ameliorates MC903-Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin.

Journal: The Journal of dermatology

Published: October 01, 2025

Spesolimab Rapidly Resolved Capillary Leak Syndrome Associated with Generalized Pustular Psoriasis.

Spesolimab Rapidly Resolved Capillary Leak Syndrome Associated with Generalized Pustular Psoriasis.

Journal: Acta dermato-venereologica

Published: September 08, 2025

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long-Term Treatment With Dupilumab: A Single-Center Retrospective Study.

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long-Term Treatment With Dupilumab: A Single-Center Retrospective Study.

Journal: The Journal of dermatology

Published: August 15, 2025

Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey.

Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey.

Journal: Cureus

Published: March 08, 2025

Effectiveness and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Single-centre Retrospective Study.

Effectiveness and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Single-centre Retrospective Study.

Journal: Acta dermato-venereologica

Published: January 07, 2025

Real-World Experience of 3-Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis.

Real-World Experience of 3-Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis.

Journal: Experimental dermatology

Published: September 03, 2024

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation.

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation.

Journal: European journal of dermatology : EJD

Published: July 17, 2024

Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.

Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.

Journal: The Journal of dermatology

Published: February 29, 2024

Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.

Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.

Journal: Experimental dermatology

Published: February 12, 2024

Impact of 1-year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis.

Impact of 1-year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis.

Journal: Experimental dermatology

Published: November 24, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026